EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

A Narrative Review of the State of the Art of CCR4-Based Therapies in Cutaneous T-Cell Lymphomas: Focus on Mogamulizumab and Future Treatments

Corrado Zengarini iD, Alba Guglielmo, Martina Mussi, Giovanna Motta iD, Claudio Agostinelli, Elena Sabattini iD, Bianca Maria Piraccini iD, Alessandro Pileri iD

Antibodies · 22.04.2024 · 13 (2) · 32

DOI: 10.3390/antib13020032 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Antibodies, online erschienen am 22.04.2024. Verfasst von Corrado Zengarini und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Surgical Sciences (DIMEC), University of Bologna, 40138 Bologna, Italy. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 122 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The CCR4 receptor is a pivotal target in cutaneous T-cell lymphoma (CTCL) therapy due to its role in impairing immune responses against malignant T-cells and expression profiles. Monoclonal antibodies like mogamulizumab effectively bind to CCR4, reducing tumour burden and enhancing patient outcomes by inhibiting the receptor’s interaction with ligands, thereby hindering malignant T-cell migration and survival. Combining CCR4 antibodies with chemotherapy, radiation, and other drugs is being explored for synergistic effects. Additionally, small-molecular inhibitors, old pharmacological agents interacting with CCR4, and CAR-T therapies are under investigation. Challenges include drug resistance, off-target effects, and patient selection, addressed through ongoing trials refining protocols and identifying biomarkers. Despite advancements, real-life data for most of the emerging treatments are needed to temper expectations. In conclusion, CCR4-targeted therapies show promise for CTCL management, but challenges persist. Continued research aims to optimise treatments, enhance outcomes, and transform CTCL management. This review aims to elucidate the biological rationale and the several agents under various stages of development and clinical evaluation with the actual known data.

Schlagwörter

Stichwörter der Autor:innen

CCR4CTCLchemokinecutaneousinflammatorylymphomamediatorsoncologyproteinskin

Autor:innen und Institutionen

  • Department of Medical and Surgical Sciences (DIMEC), University of Bologna, 40138 Bologna, Italy.
  • Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
  • Institute of Dermatology, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), 33100 Udine, Italy.
  • Division of Haematopathology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.

ORCID-Profile: Corrado Zengarini, Giovanna Motta, Elena Sabattini, Bianca Maria Piraccini, Alessandro Pileri

Zitieren

APA

Zengarini, C., Guglielmo, A., Mussi, M., Motta, G., Agostinelli, C., Sabattini, E., Piraccini, B. M., & Pileri, A. (2024). A Narrative Review of the State of the Art of CCR4-Based Therapies in Cutaneous T-Cell Lymphomas: Focus on Mogamulizumab and Future Treatments. Antibodies, 13(2), 32. https://doi.org/10.3390/antib13020032

Vancouver

Zengarini C, Guglielmo A, Mussi M, Motta G, Agostinelli C, Sabattini E, et al. A Narrative Review of the State of the Art of CCR4-Based Therapies in Cutaneous T-Cell Lymphomas: Focus on Mogamulizumab and Future Treatments. Antibodies. 2024;13(2):32. doi:10.3390/antib13020032

BibTeX
@article{Zengarini2024,
  author = {Zengarini, Corrado and Guglielmo, Alba and Mussi, Martina and Motta, Giovanna and Agostinelli, Claudio and Sabattini, Elena and Piraccini, Bianca Maria and Pileri, Alessandro},
  title = {A Narrative Review of the State of the Art of CCR4-Based Therapies in Cutaneous T-Cell Lymphomas: Focus on Mogamulizumab and Future Treatments},
  journal = {Antibodies},
  year = {2024},
  volume = {13},
  number = {2},
  pages = {32},
  doi = {10.3390/antib13020032}
}
Kostenlos starten →